TITLE

The American Orthopaedic Association Clinical Trials Curriculum

AUTHOR(S)
Diamond, Ivan R.; Murray, Camille; Bosse, Michael J.; Heckman, James D.; Mirza, Sohail K.; Peabody, Terrance D.; Saleh, Khaled J.; Swiontkowski, Marc F.; Wright, James G.
PUB. DATE
April 2009
SOURCE
Journal of Bone & Joint Surgery, American Volume;Apr2009, Vol. 91-A Issue 4, p1007
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents an overview of the rationale, objectives and design of a curriculum which was developed by the American Orthopedic Association in an effort to facilitate the advancement of clinical trials in orthopedics. An evaluation of the curriculum is offered. The importance of having well designed clinical trials which focus on orthopedics is discussed.
ACCESSION #
37614994

 

Related Articles

  • Societal responsibilities of clinical trial sponsors. Evans, Stephen; Pocock, Stuart // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p569 

    Editorial. Discusses the societal responsibilities of clinical trial sponsors. Suggestion that lack of commercial pay off is not a legitimate reason for stopping trials; How a large long term randomized trial is a substantial commitment by the sponsor, principal scientific investigators and...

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Intention-to-treat analysis: Protecting the integrity of randomization. Mahaniah, Kiame J.; Rao, Goutham // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644 

    Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the...

  • UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Craig, Fiona F; Thomas, Kim S; Mitchell, Eleanor J; Williams, Hywel C; Norrie, John; Mason, James M; Ormerod, Anthony D. // Trials;2012, Vol. 13 Issue 1, p51 

    Abstract: Background: Pyoderma gangrenosum (PG) is a rare inflammatory skin disorder characterised by painful and rapidly progressing skin ulceration. PG can be extremely difficult to treat and patients often require systemic immunosuppression. Recurrent lesions of PG are common, but the...

  • A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Lene Thorsen; Kerry Courneya; Clare Stevinson; Sophie Fosså // Supportive Care in Cancer;Sep2008, Vol. 16 Issue 9, p987 

    Abstract Introduction  We reviewed physical activity (PA) studies in prostate cancer (PC) survivors investigating (a) the effects of PA on health outcomes, (b) the prevalence of PA, and (c) the determinants of PA. Materials and methods  A systematic search of the literature...

  • Fully informed consent is impossible in surgical clinical trials. Bernstein, Mark // Canadian Journal of Surgery;Aug2005, Vol. 48 Issue 4, p271 

    This article reports that fully informed consent by patient is impossible in surgical clinical trials. Consent for an investigative procedure has 3 distinct but interrelated elements that are essentially the same as for purely therapeutic procedures: disclosure, capacity and voluntariness. It is...

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Clinical trial regulation in Argentina: overview and analysis of regulatory framework, use of existing tools, and researchers' perspectives to identify potential barriers. White, Lauren; Ortiz, Zulma; Cuervo, Luis G.; Reveiz, Ludovic // Pan American Journal of Public Health;Nov2011, Vol. 30 Issue 5, p445 

    Objective. To review and analyze the regulatory framework of clinical trial registration, use of existing tools (publicly accessible national/international registration databases), and users' perspectives to identify possible barriers to registration compliance by sponsors and researchers in...

  • Drugs tests on trial.  // Nature;4/20/2006, Vol. 440 Issue 7087, p970 

    The article reports on the changes to clinical trials by the Medicines and Healthcare Products Regulatory Agency in Great Britain. There were limitations of preclinical animal trials in determining the safety of drugs in humans, especially for humanized antibody drugs that are targeted at...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics